MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?

Key Takeaways Merck stock rose 7.4% in a month after beating Q4 earnings and sales estimates.MRK's 2026 outlook missed expectations, with EPS set to fall on higher M&A charges.Keytruda patent loss, Gardasil slump in China and the $2.5B generic hit weigh on near-term growth.Merck’s (MRK) stock has risen 7.4% in the past month. A key driver of the increase was better-than-expected fourth-quarter results and a more confident outlook for its future growth.In the fourth quarter, Merck beat estimates for both ear ...